BBIO Stock Overview
A commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
BridgeBio Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$26.18 |
| 52 Week High | US$44.32 |
| 52 Week Low | US$21.62 |
| Beta | 1.06 |
| 11 Month Change | 5.10% |
| 3 Month Change | -5.93% |
| 1 Year Change | -18.44% |
| 33 Year Change | -53.36% |
| 5 Year Change | -12.21% |
| Change since IPO | -4.97% |
Recent News & Updates
BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing
Jun 10
BridgeBio Pharma: Upping An Existing Position (Rating Upgrade)
Jun 03Recent updates
BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing
Jun 10BridgeBio Pharma: Upping An Existing Position (Rating Upgrade)
Jun 03BridgeBio Pharma: FDA Submission Acromidis And Top Line Results On Deck
Jan 11Estimating The Intrinsic Value Of BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Nov 06BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing
Jul 02New Forecasts: Here's What Analysts Think The Future Holds For BridgeBio Pharma, Inc. (NASDAQ:BBIO)
May 09Time To Worry? Analysts Just Downgraded Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Outlook
Feb 28Analysts Just Made A Major Revision To Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Revenue Forecasts
Jan 09BridgeBio stock rises as BBP-398, Lumakras combo for lung cancer gets FDA fast track status
Oct 11BridgeBio, Sentynl's Nulibry for rare disorder in children gets approval in EU
Sep 20BridgeBio Pharma: Down But Not Out
Aug 31BridgeBio starts dosing in phase 1 trial of BBP-671 for metabolic disorders
Aug 18Industry Analysts Just Upgraded Their BridgeBio Pharma, Inc. (NASDAQ:BBIO) Revenue Forecasts By 33%
Aug 10BridgeBio Pharma GAAP EPS of -$0.07 beats by $0.65, revenue of $73.75M beats by $48.75M
Aug 04BridgeBio, Sentynl's Nulibry get EMA panel nod for approval in EU
Jul 25Shareholder Returns
| BBIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.9% | -1.0% | 0.3% |
| 1Y | -18.4% | 16.3% | 18.6% |
Return vs Industry: BBIO underperformed the US Biotechs industry which returned 17.2% over the past year.
Return vs Market: BBIO underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| BBIO volatility | |
|---|---|
| BBIO Average Weekly Movement | 7.8% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 14.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BBIO has not had significant price volatility in the past 3 months.
Volatility Over Time: BBIO's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 553 | Neil Kumar | bridgebio.com |
BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).
BridgeBio Pharma, Inc. Fundamentals Summary
| BBIO fundamental statistics | |
|---|---|
| Market cap | US$4.86b |
| Earnings (TTM) | -US$538.26m |
| Revenue (TTM) | US$218.60m |
22.4x
P/S Ratio-9.1x
P/E RatioIs BBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BBIO income statement (TTM) | |
|---|---|
| Revenue | US$218.60m |
| Cost of Revenue | US$2.39m |
| Gross Profit | US$216.20m |
| Other Expenses | US$754.47m |
| Earnings | -US$538.26m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.88 |
| Gross Margin | 98.91% |
| Net Profit Margin | -246.23% |
| Debt/Equity Ratio | -165.5% |
How did BBIO perform over the long term?
See historical performance and comparison